Tango Therapeutics, Inc.
TNGX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $53,811 | $3,181 | $5,392 | $4,117 |
| % Growth | 1,591.6% | -41% | 31% | – |
| Cost of Goods Sold | $555 | $625 | $0 | $0 |
| Gross Profit | $53,256 | $2,556 | $5,392 | $4,117 |
| % Margin | 99% | 80.4% | 100% | 100% |
| R&D Expenses | $30,260 | $32,182 | $36,442 | $33,937 |
| G&A Expenses | $0 | $11,341 | $11,480 | $11,090 |
| SG&A Expenses | $8,924 | $11,341 | $11,480 | $11,090 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $39,184 | $43,523 | $47,922 | $45,027 |
| Operating Income | $14,072 | -$40,967 | -$42,530 | -$40,910 |
| % Margin | 26.2% | -1,287.9% | -788.8% | -993.7% |
| Other Income/Exp. Net | $1,802 | $2,149 | $2,688 | $3,289 |
| Pre-Tax Income | $15,874 | -$38,818 | -$39,842 | -$37,621 |
| Tax Expense | -$10 | $35 | $34 | $49 |
| Net Income | $15,884 | -$38,853 | -$39,876 | -$37,670 |
| % Margin | 29.5% | -1,221.4% | -739.5% | -915% |
| EPS | 0.143 | -0.35 | -0.36 | -0.34 |
| % Growth | 140.9% | 2.8% | -5.9% | – |
| EPS Diluted | 0.143 | -0.35 | -0.36 | -0.34 |
| Weighted Avg Shares Out | 110,966 | 110,541 | 110,301 | 108,684 |
| Weighted Avg Shares Out Dil | 110,966 | 110,541 | 110,301 | 108,684 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,097 | $1,239 | $1,614 | $1,813 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $555 | $625 | $622 | $620 |
| EBITDA | $16,429 | -$38,193 | -$41,908 | -$40,290 |
| % Margin | 30.5% | -1,200.7% | -777.2% | -978.6% |